Martin Dietrich, MD, PhD

Articles

Immunotherapy in NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations

February 6th 2023

Takeaways from the CheckMate 9LA, CheckMate 227, and POSEIDON trials focused on immunotherapy in non–small cell lung cancer.

Treatment Approaches for NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations

February 6th 2023

Meghan J. Mooradian, MD, discusses how she makes NSCLC treatment decisions based on concurrent mutations.

Clinical Insights on the Role of PD-1/PD-L1 Inhibitors in NSCLC

January 30th 2023

Martin Dietrich, MD, PhD, describes his approach to using anti-PD-1 therapies in non–small cell lung cancer.

Applying Molecular Biomarkers in Treatment Decision Making in NSCLC

January 30th 2023

An overview of the prevalence of molecular biomarkers in NSCLC and their effect on treatment decisions.

Navigating Barriers to Molecular Testing and Role of Liquid Biopsy in NSCLC

January 23rd 2023

Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.

The Role of Molecular Testing In Metastatic NSCLC

January 23rd 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.

KRAS G12C–Mutated NSCLC: Real-World Implications of Novel Targeted Therapy

December 30th 2022

Closing out their review of treatment options for KRAS G12C–mutated NSCLC, expert oncologists look toward future utilization of novel targeted agents in this setting.

2L KRAS Inhibitors for Patients With KRAS G12C–Mutated NSCLC

December 30th 2022

Centering discussion on KRAS inhibitors and associated clinical trials, Martin Dietrich, MD, PhD, and Joshua Sabari, MD, detail the second-line management of KRAS G12C–mutated non–small cell lung cancer.

Non–Small Cell Lung Cancer: Selecting 1L Therapy for Patients With KRAS G12C Mutations

December 23rd 2022

Key opinion leaders identify the first-line treatment armamentarium for patients with KRAS G12C–mutated non–small cell lung cancer.

Non–Small Cell Lung Cancer: Informing 1L Therapy Selection With Molecular Testing

December 23rd 2022

A brief review of how results from adequate molecular testing may help to inform the first-line management of non–small cell lung cancer.

Overcoming Barriers to Molecular Testing in Non–Small Cell Lung Cancer

December 16th 2022

A comprehensive discussion on how to overcome barriers that may inhibit access to adequate molecular testing in patients with non–small cell lung cancer.

Addressing Inadequate Molecular Testing in Patients With NSCLC

December 16th 2022

Expert perspectives on course-correcting the management of patients with NSCLC who may not have received adequate molecular profiling in the past.

Non–Small Cell Lung Cancer: Optimizing the Identification of KRAS G12C Mutations

December 9th 2022

Shared insight on best practices in non–small cell lung cancer management to utilize molecular testing and identify patients harboring KRAS G12C mutations.

Understanding the Nature of a KRAS G12C Mutation in NSCLC

December 9th 2022

Expert oncologists Martin Dietrich, MD, PhD, and Joshua Sabari, MD, elucidate the emergence of KRAS G12C as a molecular marker in the setting of non–small cell lung cancer.

Biomarker Testing Standards-of-Care in Breast and Lung Cancer

October 17th 2022

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.

Monitoring Patients on First-Line Treatment for Metastatic Breast Cancer

October 17th 2022

Ellen Ball, ANP-FNP, reviews how patients are monitored for treatment response and toxicities during first-line treatment.

Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations

October 10th 2022

Key opinion leaders explain how early they introduce targeted therapy in mutated breast cancer.

Further Molecular Testing in Early-Stage Metastatic Breast Cancer

October 10th 2022

Gregory Vidal, MD, PhD, discusses the potential use of further molecular testing in early-stage first-line breast cancer.

Biomarker-Influenced Treatment Approaches for Patients with Metastatic Lung Cancer

September 26th 2022

Martin Dietrich, MD, PhD, explains the rationale for the chosen treatment approach in the presented clinical scenario of metastatic lung cancer.

Clinical Scenario: A 74-Year-Old Man with Lung Cancer

September 26th 2022

A panel of experts discusses the clinical scenario of a 74-year-old man with metastatic lung cancer and the best genetic testing approach.